Drug
Solriamfetol clinical trials
Also written JZP-110 and Sunosi.
- studies test it
- 29
- open now
- 7
- in phase 3
- 13
- first study started
- 2011
Keep track of what changes. Save the solriamfetol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
28 studies that test it; most in 2024 (7)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2021 | 6 |
| 2023 | 3 |
| 2024 | 7 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 11
- Phase 3
- 13
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 9
Axsome Therapeutics, Inc. (9) · Jazz Pharmaceuticals (9) · Duke University (2) · University of Pennsylvania (1) · Rochester Center for Behavioral Medicine (1) · Ignis Therapeutics (Suzhou) Limited (1) · Massachusetts General Hospital (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses solriamfetol is read from its arms, and is right about nine times in ten.
Testing it · 29
- An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHDEnrolling by invitationPhase 3Axsome Therapeutics, Inc.NCT07773883Written as Solriamfetol
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolRecruitingPhase 3Axsome Therapeutics, Inc.NCT07484217Written as Solriamfetol 150 MG
- A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating DisorderEnrolling by invitationPhase 3Axsome Therapeutics, Inc.NCT06878976Written as Solriamfetol
- Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolRecruitingPhase 3Axsome Therapeutics, Inc.NCT06413433Written as Solriamfetol 150 mg
- Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)RecruitingPhase 3Axsome Therapeutics, Inc.NCT06568367Written as Solriamfetol 150 mg
- Solriamfetol for the Treatment of Multiple Sclerosis FatigueRecruitingPhase 2Johns Hopkins UniversityNCT06170970Written as Solriamfetol
- Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.Not yet recruitingPhase 2University Hospital, MontpellierNCT06590662Written as Solriamfetol
- RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)CompletedPhase 2Duke UniversityNCT06404099Written as Solriamfetol
- Solriamfetol and CBT-I in Patients With Insomnia DisorderCompletedPhase 4University of PennsylvaniaNCT05838430Written as Solriamfetol 75 MG
- A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)CompletedPhase 3Axsome Therapeutics, Inc.NCT05972044Written as Solriamfetol 150 mg
- Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled StudyCompletedPhase 4Axsome Therapeutics, Inc.NCT04789174Written as Solriamfetol
- RECOVER-SLEEP: Platform ProtocolCompletedPhase 2Duke UniversityNCT06404086Written as Solriamfetol
- Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolCompletedPhase 3Axsome Therapeutics, Inc.NCT06360419Written as Solriamfetol 300 mg
- Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work DisorderTerminatedPhase 4Charles A. Czeisler, PhD, MDNCT04788953Written as Solriamfetol Oral Tablet
- A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue SyndromeCompletedPhase 4Rochester Center for Behavioral MedicineNCT04622293Written as Solriamfetol Oral Tablet [Sunosi]
- A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)CompletedPhase 3Ignis Therapeutics (Suzhou) LimitedNCT06103825Written as Solriamfetol
- A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in AdultsCompletedPhase 2/3Massachusetts General HospitalNCT04839562Written as Solriamfetol 75 MG
- Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral AdministrationCompletedPhase 1Axsome Therapeutics, Inc.NCT05008341Written as Solriamfetol 150 mg Oral Tablet
- Solriamfetol in Binge Eating DisorderStatus unknownPhase 4Lindner Center of HOPENCT04602936Written as Solriamfetol
- A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime SleepinessCompletedPhase 2Jazz PharmaceuticalsNCT01485770Written as ADX-N05
Codes
What other systems call solriamfetol · ClinicalTrials.gg INT000800
- MeSH (NLM) C000623308solriamfetolConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 939U7C91AISOLRIAMFETOLConfirmed FDA, NLM, Wikidata
- RxNorm 2121751Confirmed FDA, Wikidata
- Wikidata Q39059979solriamfetolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152389SolriamfetolOne source FDA
- DrugBank DB14754One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000623308 | solriamfetol | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 939U7C91AI | SOLRIAMFETOL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2121751 | — | Confirmed FDA, Wikidata |
| Wikidata | Q39059979 | solriamfetol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152389 | Solriamfetol | One source FDA |
| DrugBank | DB14754 | — | One source Wikidata |
Also registered as solriamfetol hydrochloride (UNII K7RO88SP7A · RxNorm 2121750).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.